HC Wainwright Estimates Purple Biotech Q1 Earnings

Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) – HC Wainwright issued their Q1 2026 earnings estimates for Purple Biotech in a research report issued on Tuesday, November 18th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.39) per share for the quarter. The consensus estimate for Purple Biotech’s current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Purple Biotech’s Q2 2026 earnings at ($0.45) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.58) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Purple Biotech in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Purple Biotech Price Performance

Shares of NASDAQ PPBT opened at $0.76 on Thursday. The business has a 50-day moving average of $0.66 and a 200-day moving average of $1.70. The company has a market capitalization of $9.81 million, a price-to-earnings ratio of -1.82 and a beta of 0.64. Purple Biotech has a 1-year low of $0.53 and a 1-year high of $13.95.

Institutional Investors Weigh In On Purple Biotech

A hedge fund recently bought a new stake in Purple Biotech stock. Virtu Financial LLC purchased a new position in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 48,993 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned approximately 0.38% of Purple Biotech as of its most recent filing with the Securities & Exchange Commission. 9.64% of the stock is currently owned by institutional investors.

Purple Biotech Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.